US Stock Market Move | Q4 revenue lower than expected, Abbott Laboratories (ABT.US) drops over 7% in pre-market trading.

On Thursday, Abbott Laboratories (ABT.US) fell over 7% in pre-market trading, trading at $112.02. On the news front, the company reported that sales for the fourth quarter of 2025 were $11.46 billion, which was $340 million lower than expected. Sales grew by 4.4% based on reported basis, and organically by 3.8% after excluding the impact of COVID-19 testing. Adjusted earnings per share (EPS) for the fourth quarter reached $1.50, a 12% increase from the previous year, and full-year adjusted EPS for 2025 increased by 10% to $5.15. The company's medical device division led the growth with a 12.3% increase, mainly driven by strong performance in diabetes care and electrophysiology. For the full year of 2025, the company achieved sales of $44.3 billion, representing a 5.7% growth on a reported basis. Sales for the continuous glucose monitoring business in the fourth quarter reached $2 billion, a 15.0% growth on a reported basis. Looking ahead, the company expects organic sales growth of 6.5% to 7.5% for the full year of 2026, with adjusted earnings per share of $5.55 to $5.80, representing a 10% mid-point increase. The company anticipates completing the strategic acquisition of Exact Sciences in the second quarter of 2026, thus entering the rapidly growing cancer diagnostics market.